Lumiracoxib (Prexige) is effective in the treatment of osteoarthritis of the knee: a 13-week, placebo-controlled, active-comparator, double-blind study
H Tannenbaum, Alberto Gimona, Gyula Poór(Semmelweis University), Henning Bliddal(Frederiksberg Hospital), Jean‐Yves Reginster(King Saud University), Joseph Zacher, Alan Moore, J. Robinson(Ipswich Hospital), Françis Berenbaum(Inserm), Andrew Lee(University of Pennsylvania), Federico Navarro, Silvano Adami(University of Verona), Daniel Uebelhart(Radboud University Nijmegen)
Open Repository and Bibliography (University of Liège)
September 1, 2002
Cited by 7
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2012|2.9k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k